Sensus Healthcare, Inc. (NASDAQ:SRTS) Receives $8.00 Consensus Target Price from Analysts

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) have earned an average rating of “Hold” from the five brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $8.00.

A number of research analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a research report on Wednesday, October 8th. Zacks Research upgraded shares of Sensus Healthcare from a “strong sell” rating to a “hold” rating in a research note on Wednesday, October 22nd. Finally, Wall Street Zen raised shares of Sensus Healthcare from a “sell” rating to a “hold” rating in a report on Saturday, December 20th.

Insider Activity

In other Sensus Healthcare news, CEO Joseph C. Sardano purchased 25,000 shares of the firm’s stock in a transaction on Tuesday, November 18th. The stock was bought at an average cost of $4.03 per share, for a total transaction of $100,750.00. Following the completion of the purchase, the chief executive officer owned 1,200,293 shares in the company, valued at $4,837,180.79. This represents a 2.13% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Eric Sachetta purchased 7,000 shares of the company’s stock in a transaction dated Friday, November 21st. The shares were acquired at an average price of $3.93 per share, for a total transaction of $27,510.00. Following the purchase, the director directly owned 140,113 shares of the company’s stock, valued at approximately $550,644.09. The trade was a 5.26% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 36,500 shares of company stock worth $147,570 over the last ninety days. 8.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SRTS. Acadian Asset Management LLC raised its holdings in shares of Sensus Healthcare by 35.3% in the first quarter. Acadian Asset Management LLC now owns 470,713 shares of the company’s stock worth $2,225,000 after buying an additional 122,746 shares during the last quarter. Kingstone Capital Partners Texas LLC purchased a new position in Sensus Healthcare in the 2nd quarter worth $3,170,000. Chapin Davis Inc. lifted its position in Sensus Healthcare by 66.7% during the 2nd quarter. Chapin Davis Inc. now owns 25,000 shares of the company’s stock worth $118,000 after acquiring an additional 10,000 shares during the period. Sachetta LLC lifted its position in Sensus Healthcare by 3.0% during the 2nd quarter. Sachetta LLC now owns 128,675 shares of the company’s stock worth $610,000 after acquiring an additional 3,788 shares during the period. Finally, Evernest Financial Advisors LLC purchased a new stake in Sensus Healthcare during the 2nd quarter valued at about $255,000. Institutional investors and hedge funds own 25.30% of the company’s stock.

Sensus Healthcare Trading Up 15.0%

SRTS opened at $5.30 on Friday. The firm has a market cap of $87.03 million, a price-to-earnings ratio of -27.89 and a beta of 1.21. Sensus Healthcare has a 12 month low of $3.03 and a 12 month high of $9.08. The stock has a fifty day moving average price of $4.06 and a 200-day moving average price of $3.87.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.06. The company had revenue of $6.88 million for the quarter, compared to the consensus estimate of $6.31 million. Sensus Healthcare had a negative return on equity of 5.67% and a negative net margin of 8.44%. On average, equities research analysts forecast that Sensus Healthcare will post 0.32 EPS for the current year.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.